基本情報
- 所属
- 学校法人 自治医科大学 耳鼻咽喉科(兼任) 臨床腫瘍科 助教国立研究開発法人国立がん研究センター 東病院 頭頸部内科 外来研究員
- 研究者番号
- 50812864
- ORCID ID
https://orcid.org/0000-0002-6422-4033- J-GLOBAL ID
- 202401017612716574
- researchmap会員ID
- R000066410
研究分野
1経歴
5-
2025年4月 - 現在
-
2025年4月 - 現在
-
2022年4月 - 2025年3月
-
2016年4月 - 2022年3月
-
2014年4月 - 2016年3月
学歴
1-
2008年4月 - 2014年3月
受賞
2-
2025年2月
-
2024年3月
論文
18-
International Journal of Clinical Oncology 2025年6月24日
-
International Journal of Clinical Oncology 2025年4月10日 筆頭著者
-
International Journal of Clinical Oncology 2024年7月23日 筆頭著者
-
Frontiers in Oncology 14 2024年5月23日Background Olfactory neuroblastoma (ONB) is a rare malignant tumor of the head and neck. Due to its rarity, standard systemic therapy for this condition has yet to be established. In particular, the use of immune checkpoint inhibitors (ICIs) for the recurrent or metastatic (R/M) ONB population remains unclear. Methods We retrospectively evaluated 11 patients with R/M ONB who received any systemic chemotherapy at two Japanese institutions (National Cancer Center Hospital East and Kyushu Medical Center) between January 2002 and March 2022 and analyzed outcomes by use of anti-PD-1 antibody (nivolumab or pembrolizumab) monotherapy. Results Of the 11 patients, 6 received ICI (ICI-containing treatment group) and the remaining 5 were treated with systemic therapy but not including ICI (ICI-non-containing treatment group). Overall survival (OS) was significantly longer in the ICI-containing group (median OS: not reached vs. 6.4 months, log-rank p-value: 0.035). The fraction of ICI systemic therapy in the entire treatment period of this group reached 85.9%. Four patients (66.7%) in the ICI-containing treatment group experienced immune-related adverse events (irAE), with grades of 1/2. No irAE of grade 3 or more was seen, and no patient required interruption or discontinuation of treatment due to toxicity. Conclusion ICI monotherapy appears to be effective and to contribute to prolonged survival in R/M ONB.
-
Cureus 16(4) e58269 2024年4月When pharmacological treatments are inadequate, facial nerve paralysis from various etiologies, including Bell's palsy, Hunt syndrome, and trauma, often requires surgical intervention. Facial nerve decompression surgery aims to relieve nerve compression and restore function, with preserving hearing function, especially in pediatric cases, being crucial. Conventional methods, like the transmastoid approach, risk affecting auditory function due to ossicle manipulation. Herein, we describe the case of a 12-year-old boy with left facial palsy diagnosed with zoster sine herpete (ZSH) syndrome. Despite medical treatment, the patient's condition did not improve, prompting facial nerve decompression surgery. Employing the intact transmastoid ossicle (ITO) swaying technique, we minimized ossicular manipulation, preserving auditory function while effectively achieving facial nerve decompression. The patient demonstrated improvement postoperatively in auditory and facial nerve functions. Furthermore, audiometric assessments demonstrated no substantial deterioration in hearing thresholds, and the facial nerve function improved from Grade V to Grade II on the House-Brackmann scale. The ITO technique provides a less invasive alternative compared to conventional approaches, lowering the chance of the ossicular chain and the risk of postoperative hearing loss. This case highlights the significance of customized surgical approaches in pediatric facial nerve decompression surgery, resulting in improved patient outcomes. Further research is required to validate the efficacy and safety of this method across various clinical contexts.
-
In Vivo 37(5) 2320-2326 2023年8月31日
-
Case Reports in Oncology 16(1) 224-232 2023年4月14日
-
Acta Oto-Laryngologica Case Reports 2022年12月31日 筆頭著者
-
Case Reports in Oncology 15(2) 776-782 2022年8月30日
-
BMJ Case Reports 15(6) 2022年6月
-
小児耳鼻咽喉科 41(1) 70-74 2020年 査読有り筆頭著者小児甲状舌管癌は頻度が少なく，再発症例はさらに稀である。今回2度再発を反復した症例を経験したので報告する。初発時12歳の男児。甲状舌管から右頸部にかけての乳頭癌に対し甲状腺右葉切除術，Sistrunk手術，頸部郭清術を併施した。右葉には原発巣を認めず甲状舌管癌と診断した。13歳時に頸部リンパ節再発し，頸部郭清術を施行した。今回，経過観察中の21歳時に甲状腺左葉へ乳頭癌の転移再発を認め，左葉切除術を施行した。甲状腺が原発巣であった可能性を完全には否定できないものの，超音波所見の推移から可能性は極めて低いと考える。初回治療の議論や左葉病変の臨床的及び病理学的な検討を含め考察する。
MISC
43-
ESMO Asia Congress 2024_#2183 35 S1561-S1561 2024年12月
-
Journal of Clinical Oncology 42(16_suppl) 6034-6034 2024年6月1日 筆頭著者6034 Background: Extranodal extension (ENE) of nodal metastasis is a significant prognostic factor in p16-negative SCCHN and is classified as N3b by the AJCC 8th edition. Therefore, pretreatment determination of ENE has significant clinical implications in SCCHN, and iENE has just recently been proposed. We previously discussed association with pathological ENE and iENE (Jpn J Radiol. 2020;38(6):489-506.). However, the role of iENE in non-surgical sequential therapy remains unclear. Methods: We retrospectively reviewed patients with LASCCHN originating from the oropharynx, hypopharynx, and larynx who received enhanced computed tomography (CT), then treated with induction chemotherapy (IC) with paclitaxel, carboplatin, and cetuximab followed by chemoradiotherapy (CRT) from 2013 to 2022 in our hospital. Two radiologists specializing in head and neck cancer blindly annotated the status of iENE in baseline CT images by the previously reported criteria (Oral Oncol. 2022;125:105716.). Multivariate analysis variables for event-free survival (EFS) and overall survival (OS) included the presence or absence of iENE, a response to IC, clinical T-category, performance status, smoking status, etc. Results: In the 88 patients, 67 (76.1%) had iENE and 21 (23.9%) did not at baseline. In the former and latter group, stage II/III/IV were 10.4%/26.9%/62.7% and 0%/28.6%/71.4%, HPV-positive were 37.3% and 28.6%, respectively. With the median follow-up of 37.4 months (range: 6.7-108.8), the former had significantly shorter EFS (3-y EFS: 41.9% vs. 75.6%, hazard ratio [HR]; 2.9 (1.2-7.4), p-value; 0.02) and OS (3-y OS: 72.8% vs. 100%, HR; Inf (0.01-Inf), p-value=0.003). Multivariate analysis identified the presence of iENE (HR for EFS: 2.80, 95%CI: 0.97-8.05, HR for OS: 2.93, 95%CI: 1.01-8.44) and unresponsiveness to IC (HR for EFS: 2.47, 95%CI: 1.31-4.68, HR for OS: 2.87, 95%CI: 1.13-7.26) as mutually independent unfavorable prognostic factors for both EFS and OS. Furthermore, classification based on the two factors could identify the population with a worse prognosis (Table). Conclusions: In the sequential therapy of IC followed by CRT, the current study revealed for the first time that subjects with an iENE at baseline, together with an unsatisfactory response to IC would require special attention, such as more intensified post-treatment follow-up as well as additional therapeutic interventions to improve their prognosis. [Table: see text]